Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Interference01:23

RNA Interference

26.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
Types of RNA01:23

Types of RNA

64.3K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
64.3K
Translational Regulation01:29

Translational Regulation

69
Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
69
RNA Stability01:53

RNA Stability

33.8K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
33.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.

Chemical research in toxicology·2024
Same author

Prediction of In Vivo Pharmacokinetic Parameters and Time-Exposure Curves in Rats Using Machine Learning from the Chemical Structure.

Molecular pharmaceutics·2022
Same author

High-throughput detection of metal contamination in HTS outputs.

SLAS discovery : advancing life sciences R & D·2022
Same author

Target-Directed Approaches for Screening Small Molecules against RNA Targets.

SLAS discovery : advancing life sciences R & D·2020
Same author

Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies.

Journal of medicinal chemistry·2019
Same author

Site-Specific Fluorophore Labeling of Guanosines in RNA G-Quadruplexes.

ACS omega·2019

Related Experiment Video

Updated: Aug 14, 2025

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
11:58

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Published on: January 30, 2019

8.4K

Targeting RNA with small molecules-A safety perspective.

Helen L Lightfoot1, Graham F Smith2

  • 1Safety and Mechanistic Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.

British Journal of Pharmacology
|January 11, 2023
PubMed
Summary

Small molecule-RNA targeting (smRNA targeting) is a promising drug discovery approach. This work explores RNA as a secondary target to develop safer small molecule drugs.

Keywords:
ribonucleic acidsecondary structuresmall molecules

More Related Videos

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.9K
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K

Related Experiment Videos

Last Updated: Aug 14, 2025

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
11:58

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Published on: January 30, 2019

8.4K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.9K
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K

Area of Science:

  • Molecular Biology
  • Drug Discovery
  • Medicinal Chemistry

Background:

  • Ribonucleic acid (RNA) plays critical roles in cellular functions and disease.
  • Small molecule-RNA targeting (smRNA targeting) has emerged as a significant therapeutic strategy.
  • Current drug discovery efforts primarily focus on RNA as a primary target.

Purpose of the Study:

  • To explore the largely uninvestigated role of RNA as a secondary (off) target in small molecule drug programs.
  • To discuss structure, target, and mechanism-driven safety considerations for smRNA therapeutics.
  • To highlight methods for evaluating these parameters to enhance drug safety.

Main Methods:

  • Literature review and perspective synthesis.
  • Analysis of structure-activity relationships in smRNA targeting.
  • Discussion of target and mechanism-based safety profiling.

Main Results:

  • RNA is frequently an off-target in small molecule drug development, presenting both risks and opportunities.
  • Understanding smRNA interactions requires detailed analysis of molecular structure, target engagement, and mechanism of action.
  • Safety can be proactively managed by considering RNA as a potential off-target.

Conclusions:

  • Evaluating RNA as a secondary target can lead to the development of safer small molecule drugs.
  • Integrating safety assessments early in drug discovery is crucial for smRNA therapeutics.
  • This perspective provides a framework for considering RNA off-target effects to improve drug safety profiles.